Neprilysin inhibition in chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 30, Issue 5, 2015, Pages 738-743

  Judge, Parminder ^a   Haynes, Richard ^a   Landray, Martin J ^a   Baigent, Colin ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cardiovascular disease; chronic kidney disease; heart failure; hypertension; neprilysin inhibition

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR; CANDOXATRILAT; ENALAPRIL; ENKEPHALINASE INHIBITOR; ILEPATRIL; IRBESARTAN; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR; OMAPATRILAT; PLACEBO; SACUBITRIL; SACUBITRIL PLUS VALSARTAN; UNCLASSIFIED DRUG; VALSARTAN; VASOPEPTIDASE INHIBITOR; AMINOBUTYRIC ACID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PYRIDINE DERIVATIVE; TETRAZOLE DERIVATIVE; THIAZEPINE DERIVATIVE;

ANGIONEUROTIC EDEMA; ARTICLE; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASE; CHEMISTRY; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG EFFECTS; HEART FAILURE; KIDNEY FAILURE, CHRONIC; METABOLISM; NATRIURESIS; NEPHROLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEINURIA; TRENDS;

AMINOBUTYRATES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HEART FAILURE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; NATRIURESIS; NEPHROLOGY; NEPRILYSIN; PROTEINURIA; PYRIDINES; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; THIAZEPINES; TREATMENT OUTCOME;

EID: 84929580074     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu269     Document Type: Article

References (43)

1. Weiner DE, Tighiouart H, Stark PC et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004; 44: 198-206
2. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382: 339-352
3. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462
4. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-364
5. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
6. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
7. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153
8. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-1535
9. Kowey PR, Dickson TZ, Zhang Z et al. Losartan and end-organ protection-lessons from the RENAAL study. Clin Cardiol 2005; 28: 136-142
10. Kunz R, Friedrich C, Wolbers M et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48
11. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
12. Fried LF, Emanuele N, Zhang JH et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369: 1892-1903
13. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553
14. Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213
15. Sager G. Cyclic GMP transporters. Neurochem Int 2004; 45: 865-873
16. Mangiafico S, Costello-Boerrigter LC, Andersen IA et al. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 2013; 34: 886-893c
17. Wilkins MR, Redondo J, Brown LA. The natriuretic-peptide family. Lancet 1997; 349: 1307-1310
18. Stockand JD, Sansom SC. Regulation of filtration rate by glomerular mesangial cells in health and diabetic renal disease. Am J Kidney Dis 1997; 29: 971-981
19. Melo LG, Veress AT, Chong CK et al. Salt-sensitive hypertension in ANP knockout mice: potential role of abnormal plasma renin activity. Am J Physiol 1998; 274: R255-R261
20. Lin KF, Chao J, Chao L. Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in Dahl salt-sensitive rats. Hypertension 1999; 33: 219-224
21. Lin KF, Chao J, Chao L. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats. Hum Gene Ther 1998; 9: 1429-1438
22. Cannone V, Boerrigter G, Cataliotti A et al. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol 2011; 58: 629-636
23. Benigni A, Zoja C, Zatelli C et al. Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. Kidney Int 2004; 66: 1959-1965
24. Cao Z, Burrell LM, Tikkanen I et al. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomised rats. Kidney Int 2001; 60: 715-721
25. Taal MW, Nenov VD, Wong W et al. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 2001; 12: 2051-2059
26. Neal B, MacMahon S, Ohkubo T et al. Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease. J Renin Angiotensin Aldosterone Syst 2002; 3: 270-276
27. Kostis JB, Packer M, Black HR et al. Omapatrilat and enalapril in patients with hypertension: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17: 103-111
28. Agostoni A, Cicardi M, Cugno M et al. Angioedema due to angiotensinconverting enzyme inhibitors. Immunopharmacology 1999; 44: 21-25
29. Hoover T, Lippmann M, Grouzmann E et al. Angiotensin converting enzyme inhibitor induced angio-oedema: A review of the pathophysiology and risk factors. Clin Exp Allergy 2010; 40: 50-61
30. Byrd JB, Touzin K, Sile S et al. Dipeptidyl peptidase IV in angiotensinconverting enzyme inhibitor associated angioedema. Hypertension 2008; 51: 141-147
31. McMurray JJ, Packer M, Desai AS et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013; 15: 1062-1073
32. Gu J, Noe A, Chandra P et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010; 50: 401-414
33. Ruilope L, Dukat A, Böhm M et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010; 375: 1255-1266
34. Kario K, Sun N, Chiang FT et al. Efficacy and safety of LCZ696, a first-inclass angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: A randomized, double-blind, placebo-controlled study. Hypertension 2014; 63: 698-705
35. Williams B, Cockcroft JR, Kario K et al. Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study. BMJ Open 2014; 4: e004254
36. Packer M, Califf RM, Konstam MA et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106: 920-926
37. Solomon SD, Zile M, Pieske B et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387-1395
38. Vardeny O, Tacheny T, Solomon SD. First-in-class angiotensin receptor neprilysin inhibitor in heart failure. Clin Pharmacol Ther 2013; 94: 445-448
39. McMurray JJ, Packer M, Desai AS et al. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2014; doi:10.1002/ejhf.115.41
40. Novartis. PARADIGM-HF trial of Novartis' LCZ696 for chronic heart failure closes early based on strength of interim results. http://www. novartis.com (1 April 2014, date last accessed)
41. Davis BJ, Johnston CI, Burrell LM et al. Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia 2003; 46: 961-971
42. Lipkin G, Dawnay AB, Harwood SM et al. Enhanced natriuretic response to neutral endopeptidase inhibition in patients with moderate chronic renal failure. Kidney Int 1997; 52: 792-801
43. Rouleau JL, PfefferMA, Stewart DJ et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS